[PDF] Top 20 The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
Has 10000 "The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients" found on our website. Below are the top 20 most common "The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients".
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
... and PD-L2 expression are up-regulated in a variety of human cancer ...types. PD-L1 is frequently expressed in several types of solid tumor cells, whereas PD-L2 is highly expressed in ... See full document
12
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
... overall response rate was ...of patients with unresectable or metastatic melanoma and disease progression following Ipilimumab (anti- CTL4 antibody), and for B-Raf proto-oncogene, serine/ threonine ... See full document
12
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
... ovarian cancer, and Hodgkin lymphoma FFPE specimens studied by IHC/IF; [27, 30–32] and melan- oma, renal cell carcinoma, and MCC specimens studied by flow cytometry ...that PD-L1 engagement of ... See full document
11
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report
... the response to PD-1 blockade immunotherapy ...the PD-1 blockade immunotherapy, such as weak PD-L1 ex- pression, MSI and TMB-low, had indicated invalid im- ... See full document
6
Expression of PD L1 in triple negative breast cancer based on different immunohistochemical antibodies
... in patients with non-small cell lung cancer (NSCLC) treated with EGFR ...Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, ... See full document
12
Anti–PD 1/PD L1 therapy of human cancer: past, present, and future
... the PD pathway has been broadly categorized together with CTLA-4 as an “immune ...However, anti-PD therapy is based on completely different scientific prin- ciples compared with ... See full document
9
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
... multiple cancer types and provides promising clinical responses, durable disease control, and fewer adverse events among patients with advanced melanoma, non- small cell lung cancer (NSCLC), and ... See full document
8
Host expression of PD L1 determines efficacy of PD L1 pathway blockade–mediated tumor regression
... host PD-L1 and PD-1 pathway in PD-L1 and PD-1 blockade ...tissue PD-L1 expression (including PD-L1 expression in all types of cells) ... See full document
12
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1
... the immune system, especially for the selection of T-cells with appropriate ...of PD-L1 expression [8, 9]. Many different clones of PD-L1 antibodies have been tested in different ... See full document
12
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
... the PD-1/PD-L1 pathway has elicited durable antitumor responses in the therapy of a broad spectrum of ...cancers. PD-L1 is constitutively expressed in certain tumors and host ... See full document
8
Frameshift events predict anti–PD-1/L1 response in head and neck cancer
... coupled response with targeted sequencing data and show that TMB predicts checkpoint inhibitor response among virus-negative tumors — in line with observations reported in lung cancer ... See full document
14
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
... therapy versus indefinite pemetrexed maintenance therapy alone. At disease progression, those patients in the peme- trexed alone group were allowed for crossover to receive pembrolizumab. The primary endpoint was ... See full document
8
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
... Lung cancer is the leading cause of cancer death in males and the second leading cause of death in females ...lung cancer (NSCLC) is the main patho- logical type of lung cancer, and most newly ... See full document
14
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
... Monoclonal antibodies that block immune regulatory proteins such as programmed death-1 (PD-1) have demonstrated remarkable efficacy in controlling the growth of multiple tumor ... See full document
5
<p>A meta-analysis of the efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer</p>
... bladder cancer have few treatment choices and low survival rates, particularly after standard PBCT ...bladder cancer. Both the unmet need for second-line therapies for bladder cancer and a resurgence ... See full document
11
Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
... IHC antibodies, interpretations (expression on tumor cells, immune cells or both) and thresholds for ...for PD-L1 positivity using four different PD-L1 IHC assays, 22C3, 28-8, ... See full document
12
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
... community. PD-L1, typically expressed on the surface of healthy cells, binds PD-1 on primed cytotoxic T cells thereby inhibiting cell-mediated attack ...ing PD-L1 [2, ...against ... See full document
6
PD1/PDL-1 Inhibitors: Emerging Hope for Bladder Cancer
... better response and ...7% patients. TRAEs led to therapy interruption in 34% of patients, discontinuation in ...significant response seen at follow up of 17 months compared to initial analysis ... See full document
10
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
... different PD-1 and PD-L1 inhibitors in several solid tumor and hematological malignancies as of May 2017, it is anticipated that clinical decisions facing patients and physicians as ... See full document
5
Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials
... Our findings must be interpreted cautiously since all included studies have high risk of bias, especially perfor- mance and detection bias. These systematic errors could overestimate or underestimate the association ... See full document
11
Related subjects